Biotech Briefings
Mechanism-first notes on clinical-stage biotech, regulatory events and evidence-changing readouts. Get this by email →
Clinical Trials News
A daily, plain-language digest of new oncology and life-sciences clinical trials, with a weekly deep-dive roundup — every update linked to its trial registry or primary source.
How to read a biotech briefing
A development update is most useful when the claim is separated from the evidence behind it. GeneAnalyses tracks the molecular target, tumour or disease setting, development phase, endpoint, comparator and source date. A press release can identify that an event occurred; a trial registry, regulator document or primary publication is needed to understand the design and limitations.
Commercial relevance is not the same as clinical benefit. Early response data may change with follow-up, subgroup findings may not generalise to the full population, and regulatory status can change. Briefings are educational research notes, not investment, diagnosis or treatment advice.
EGFR resistance
Distinguish on-target mutations, bypass signalling and histologic change.
KRAS G12C in colorectal cancer
See why tumour lineage and combination evidence matter.
How to interpret a gene finding
Move from a symbol to variant, mechanism and evidence boundaries.